INTRODUCTION
Adrenocortical carcinoma (ACC) is a rare and highly aggressive malignant neoplasm with an incidence rate of 1 to 2 cases per million people per year.
1,2 The overall 5-year survival is poor, ranging from 15-44% in reported series. 3 Multimodality imaging with echocardiogram, computerized tomography (CT), positron emission tomography (PET) and magnetic resonance imaging (MRI) aids not only in establishing the diagnosis but also in anatomic evaluation to determine best surgical approach. We report a case of a large ACC with extension into the inferior vena cava (IVC) and right atrium (RA).
CASE REPORT
A 42-year-old male with medical history of hypertension and pre-diabetes presented with a 3-month history of fatigue and intermittent abdominal pain without exacerbating or relieving factors. Physical examination revealed right sided abdominal fullness but no palpable mass. Laboratory studies, including cortisol and urine metanephrine levels, were unremarkable. CT of the abdomen revealed a large right adrenal mass with contiguous tumor thrombus extending into IVC and right atrium RA with extension to the level of tricuspid valve (TV) (Fig.1A and 1B) . Transthoracic (Fig. 1C ) and transesophageal echocardiogram (Fig. 1D) showed a heterogeneous mass in the RA prolapsing through the TV into the right ventricle. Patient underwent combined cardiac and abdominal surgical intervention on cardiopulmonary bypass with removal of the intracardiac tumor and retroperitoneal mass as well as thrombectomy and dissection of the IVC (Fig.1E) . Histopathology showed ACC with neuroendocrine differentiation. The post-operative course was uneventful and he was scheduled to initiate adjuvant treatment with mitotane.
DISCUSSION
Adrenocortical carcinoma is a rare and highly aggressive malignant neoplasm which can produce tumor thrombus extension into the IVC, rarely invade the RA and exceptionally extend across the tricuspid valve. [3] [4] [5] Nearly 60% of these tumors present with a clinical syndrome of hormone excess (i.e., Cushing's syndrome, virilization). When nonfunctional, ACC may present with the clinical manifestations related to tumor growth (abdominal pain/fullness) or as an incidental radiological finding.
1 Hormonal evaluation, even in asymptomatic patients, is recommended to determine the secretory activity of the tumor. 6, 7 As initial study, CT imaging can distinguish benign from malignant adrenal tumors. The high lipid content in adenomas results in low attenuation in nonenhanced CT. Conversely, carcinomas, having less intracytoplasmic fat, will have higher attenuation and greater Hounsfield units than adenomas. Carcinomas also tend to have irregular shape and be of larger size (>4 cm). On delayed contrast-enhanced CT, adrenal carcinomas (as well as other nonadenomas) have delayed washout of contrast material. 8 MRI also has some added utility in identifying adrenal carcinomas. On conventional MRI, ACC shows equal intensity as liver on T1-weighted images and increased intensity on T2-weighted images. On gadolinium enhanced images malignant lesions show rapid and marked enhancement and a slower washout pattern. With MRI, involvement of the vena cava and cardiac structures is readily identifiable, hence its utility in surgical planning.
9
PET scanning with fluorodeoxyglucose (FDG-PET), especially when combined with CT, can be highly valuable in cases where an adrenal mass is very suspicious for malignancy. Adrenal carcinomas uptake FDG avidly, however pheochromocytomas and adrenal metastases do so as well. Alternative PET scan tracers, such as 11C-metomidate [MTO] might further improve specificity, by binding to specific enzymes only present in adrenocortical region.
Precise radiological and echocardiographic evaluation of the extent of the tumor is essential to determine surgical approach. Complete surgical resection is the only curative option for localized disease. In cases of cavo-atrial extension complete resection using cardiopulmonary bypass is recommended. 10 The prognosis of patients with ACC is generally poor. The overall 5year survival is poor, ranging from 15-44% in reported series. 3 Given the scarcity of cases there is no conclusive evidence concerning the impact of IVC and atrial involvement in patients with ACC.
